Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 10Breast Neoplasms 8Colorectal Neoplasms 7Prostatic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Neoplasms 4Melanoma 4COVID-19 4Multiple Myeloma 3Lung Neoplasms 3Colonic Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 2Solid Tumor 2Recurrence 2Rectal Neoplasms 2Ovarian Neoplasms 2Neoplasms, Plasma Cell 2Neoplasm Metastasis 2Leukemia 2Glioblastoma 2Gastrointestinal Neoplasms 2Carcinoma, Renal Cell 2Adenocarcinoma of Lung 2Adenocarcinoma 2Urologic Diseases 1Untreated Resectable Pancreatic Adenocarcinoma 1Small Cell Lung Carcinoma 1Sarcoma 1Resectable Localized Prostate Cancer 1Refractory or Relapsed Solid Tumors 1

Interventions

Oxaliplatin 32Fluorouracil 24Gemcitabine 23Leucovorin 19Docetaxel 19pembrolizumab 17Capecitabine 15Radiotherapy 14Irinotecan 13Cisplatin 11Bevacizumab 11Nivolumab 8130-nm albumin-bound paclitaxel 8Trastuzumab 7Erlotinib Hydrochloride 7Cyclophosphamide 7Albumin-Bound Paclitaxel 7Radiosurgery 6Paclitaxel 6Taxes 5S 1 (combination) 5Metformin 5Carboplatin 5Blood Specimen Collection 5Sunitinib 4Sorafenib 4Pemetrexed 4Esophagectomy 4Chemoradiotherapy 4Cetuximab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma × Hydroxychloroquine × Clear all
NCT01506973 2025-07-25

A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer

Abramson Cancer Center at Penn Medicine

Phase 1/2 Completed
119 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT01206530 2019-04-18

FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer

Abramson Cancer Center at Penn Medicine

Phase 1/2 Completed
50 enrolled
Gastrointestinal

Adenocarcinoma, Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡